These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17443703)

  • 1. Low plasma uric acid level in Parkinson's disease.
    Annanmaki T; Muuronen A; Murros K
    Mov Disord; 2007 Jun; 22(8):1133-7. PubMed ID: 17443703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.
    Andreadou E; Nikolaou C; Gournaras F; Rentzos M; Boufidou F; Tsoutsou A; Zournas C; Zissimopoulos V; Vassilopoulos D
    Clin Neurol Neurosurg; 2009 Nov; 111(9):724-8. PubMed ID: 19632030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on uric acid and the related factors associated with cognition in the patients with Parkinson's disease].
    Wang XJ; Luo WF; Wang LJ; Mao CJ; Wang L; Liu CF
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(23):1633-5. PubMed ID: 19957513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uric acid in Parkinson's disease.
    Schlesinger I; Schlesinger N
    Mov Disord; 2008 Sep; 23(12):1653-7. PubMed ID: 18618666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression.
    Ikeda K; Nakamura Y; Kiyozuka T; Aoyagi J; Hirayama T; Nagata R; Ito H; Iwamoto K; Murata K; Yoshii Y; Kawabe K; Iwasaki Y
    Neurodegener Dis; 2011; 8(4):252-8. PubMed ID: 21282940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteine elevation in levodopa-treated patients with Parkinson's disease.
    Müller T; Kuhn W
    Mov Disord; 2009 Apr; 24(6):929-32. PubMed ID: 19243072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uric acid associates with cognition in Parkinson's disease.
    Annanmaki T; Pessala-Driver A; Hokkanen L; Murros K
    Parkinsonism Relat Disord; 2008 Nov; 14(7):576-8. PubMed ID: 18321759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease].
    Larumbe Ilundáin R; Ferrer Valls JV; Viñes Rueda JJ; Guerrero D; Fraile P
    Rev Esp Salud Publica; 2001; 75(1):43-53. PubMed ID: 11400414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.
    Duran R; Barrero FJ; Morales B; Luna JD; Ramirez M; Vives F
    Mov Disord; 2010 Mar; 25(4):489-93. PubMed ID: 20063406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relation of testosterone levels with fatigue and apathy in Parkinson's disease.
    Kenangil G; Orken DN; Ur E; Forta H; Celik M
    Clin Neurol Neurosurg; 2009 Jun; 111(5):412-4. PubMed ID: 19131155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey.
    Winquist A; Steenland K; Shankar A
    Mov Disord; 2010 May; 25(7):932-6. PubMed ID: 20310031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition.
    Triantafyllou NI; Nikolaou C; Boufidou F; Angelopoulos E; Rentzos M; Kararizou E; Evangelopoulos ME; Vassilopoulos D
    Parkinsonism Relat Disord; 2008; 14(4):321-5. PubMed ID: 18055246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients.
    Sun CC; Luo FF; Wei L; Lei M; Li GF; Liu ZL; LE WD; Xu PY
    Chin Med J (Engl); 2012 Feb; 125(4):583-7. PubMed ID: 22490478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
    Ahlskog JE; Uitti RJ; Low PA; Tyce GM; Nickander KK; Petersen RC; Kokmen E
    Mov Disord; 1995 Sep; 10(5):566-73. PubMed ID: 8552107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body composition in advanced-stage Parkinson's disease.
    Petroni ML; Albani G; Bicchiega V; Baudo S; Vinci C; Montesano A; Izzo G; Bertocco P; Mazzotta S; Zorzetto E; Balzola F; Mauro A
    Acta Diabetol; 2003 Oct; 40 Suppl 1():S187-90. PubMed ID: 14618469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
    Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.
    Vieru E; Köksal A; Mutluay B; Dirican AC; Altunkaynak Y; Baybas S
    Neurol Sci; 2016 May; 37(5):743-7. PubMed ID: 26753800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uric acid and cognition in Parkinson's disease: a follow-up study.
    Annanmaki T; Pohja M; Parviainen T; Hakkinen P; Murros K
    Parkinsonism Relat Disord; 2011 Jun; 17(5):333-7. PubMed ID: 21320793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa.
    Agil A; Durán R; Barrero F; Morales B; Araúzo M; Alba F; Miranda MT; Prieto I; Ramírez M; Vives F
    J Neurol Sci; 2006 Jan; 240(1-2):31-6. PubMed ID: 16219327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Punding prevalence in Parkinson's disease.
    Miyasaki JM; Al Hassan K; Lang AE; Voon V
    Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.